Future work will further probe the mechanism of epithelial lineage plasticity induced by TFE3-fusions and continue to refine the conditions in which mTOR kinase inhibition may have therapeutic efficacy in human fusion-driven tRCC and PEComas. Here, TFE3 is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.